Linda Singer, a partner at Motley Rice, a law firm that represents multiple states, counties and municipalities in the federal opioid litigation involving Walmart and other large pharmacy chains, alleged that Walmart engaged in “pervasive obstruction” in a letter sent last month to Special Master David Cohen, the man in charge of gathering evidence in the federal opioid trial.
Ms. Singer said Walmart hasn’t produced all of its documents about its opioid prescriptions and that it hasn’t given information requested by plaintiffs about Brad Nelson, Walmart’s opioid compliance manager who became a criminal target in a federal investigation, according to ProPublica.
The plaintiffs in the federal opioid trial, which is overseen by U.S. District Judge Dan Polster in Cleveland, are seeking to have the court sanction Walmart for its behavior.
“These allegations by the plaintiffs in the ongoing Opioid MDL litigation are without merit and are part of an ongoing discovery dispute. Walmart will respond to these claims under the process set forth by the Special Master,” a Walmart spokesperson told ProPublica.
Becker’s Hospital Review has reached out to Walmart for additional comment and will update this article accordingly.
Read the full article here.
More articles on pharmacy:
Death penalty states hoarding drugs needed to ventilate COVID-19 patients
UnitedHealthcare to pay Ohio pharmacists as medical providers
Purdue University grants early graduation to 144 pharmacy students
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.